Related Experiment Video
Updated: Jun 11, 2025
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
Gene expression profiles, potential targets and treatments of cardiac remodeling
Dong Fan1, Han Feng2, Mengyu Song3
1Department of Pathophysiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519041, China. dongfan@zmuzh.edu.cn.
Insights
This review explores gene expression changes in cardiac remodeling, a key process in heart failure. Understanding these molecular mechanisms aids in developing new treatments for heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Genomics
Background:
- Hypertensive and ischemic heart diseases are leading causes of heart failure and mortality worldwide.
- Cardiac remodeling, involving hypertrophy, fibrosis, and cell death, is central to these conditions.
- Animal models are crucial for studying myocardial remodeling processes.
Purpose of the Study:
- To review recent advancements in gene expression profiling of cardiac remodeling.
- To elucidate molecular mechanisms, gene functions, and signaling pathways involved in myocardial remodeling.
- To discuss therapeutic strategies targeting gene expression in heart disease.
Main Methods:
- RNA sequencing and differentially expressed gene (DEG) analyses are key tools.
- Investigation of myocardial remodeling induced by pressure overload, ischemia-reperfusion, myocardial infarction, and diabetes.
- Analysis of sex differences and inflammation in gene regulation during remodeling.
Main Results:
- Gene expression profiling reveals molecular insights into distinct stages of cardiac remodeling.
- Identification of key signaling pathways and gene functions associated with heart failure.
- Understanding of how sex and inflammation influence gene expression in cardiac remodeling.
Conclusions:
- Gene expression profiling offers potential targets for drug screening in heart failure.
- Modulating gene expression presents emerging therapeutic strategies for myocardial remodeling.
- Further research into DEGs and regulatory mechanisms can advance cardiovascular disease treatment.
Abstract:
Hypertensive and ischemic heart diseases have high morbidity all over the world, and they primarily contribute to heart failure associated with high mortality. Cardiac remodeling, as a basic pathological process in heart diseases, is mainly comprised of cardiac hypertrophy and fibrosis, as well as cell death which occurs especially in the ischemic cardiomyopathy. Myocardial remodeling has been widely investigated by a variety of animal models, including pressure overload, angiotensin II stimulation, and myocardial infarction. Pressure overload can cause compensatory cardiac hypertrophy at the early stage, followed by decompensatory hypertrophy and heart failure at the end. Recently, RNA sequencing and differentially expressed gene (DEG) analyses have been extensively employed to elucidate the molecular mechanisms of cardiac remodeling and related heart failure, which also provide potential targets for high-throughput drug screenings. In this review, we summarize recent advancements in gene expression profiling, related gene functions, and signaling pathways pertinent to myocardial remodeling induced by pressure overload at distinct stages, ischemia-reperfusion, myocardial infarction, and diabetes. We also discuss the effects of sex differences and inflammation on DEGs and their transcriptional regulatory mechanisms in cardiac remodeling. Additionally, we summarize emerging therapeutic agents and strategies aimed at modulating gene expression profiles during myocardial remodeling.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:29Cardiomyopathy V: Interprofessional Care